When an industry is new, there are no established paths. Leaders must create novel strategies for partnerships, IPOs, and international collaborations from scratch, turning a lack of precedent into an advantage for innovation.
Related Insights
Major platform shifts like AI reward founders who are not burdened by historical context or "how things have been done before." This creates an environment where young, inexperienced teams working with high intensity (e.g., "9-9-6") can out-innovate incumbents with existing business models.
Corporate creativity follows a bell curve. Early-stage companies and those facing catastrophic failure (the tails) are forced to innovate. Most established companies exist in the middle, where repeating proven playbooks and playing it safe stifles true risk-taking.
Success in startups often bypasses mid-career managers. It's concentrated among young founders who don't know the rules and thus break them, creating disruption, and veteran founders who know all the rules and can strategically exploit market inefficiencies based on decades of experience.
The transition from a resource-rich environment like Novartis to an early-stage biotech reveals a stark contrast. The unlimited access to a global organization is replaced by a total reliance on a small, nimble team where everyone must be multi-skilled and hands-on, a change even experienced executives find jarring.
Responding to Wall Street pressure to de-risk, large pharmaceutical firms cut internal early-stage research. This led to an exodus of talent and the rise of contract research organizations (CROs), creating an infrastructure that, like cloud computing for tech, lowered the barrier for new biotech startups.
Faced with China's superior speed and cost in executing known science, the U.S. biotech industry cannot compete by simply iterating faster. Its strategic advantage lies in
Tubulus co-founders decided to launch their company after a single successful experiment, driven by passion rather than a thorough market analysis. This 'healthy naivety' helped them push forward despite industry skepticism towards their antibody-drug conjugate (ADC) technology at the time, which was considered a difficult area.
Many iconic founders, like Southwest's Herb Kelleher, were beginners in their industries. This lack of experience was an advantage, freeing them from established dogmas and allowing them to approach problems with a fresh perspective. They built unconventional models that incumbents dismissed or couldn't replicate.
The industry over-celebrates financial winners. Equal praise should be given to leaders who, despite poor financial outcomes, successfully pioneer new scientific ground or persevere to get a drug approved for a high unmet need. Their work provides crucial groundwork for future successes.
Successful people with unconventional paths ('dark horses') avoid rigid five or ten-year plans. Like early-stage founders, they focus on making the best immediate choice that aligns with their fulfillment, maintaining the agility to pivot. This iterative approach consistently outperforms fixed, long-term roadmaps.
